Asthma & Allergy Research Group, Department of cardiovascular & lung biology, Division of medicine, Ninewells Hospital & Medical School
Welcome,         Profile    Billing    Logout  
 2 Trials 
2 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipworth, Brian
WAYPOINT, NCT04851964 / 2020-003062-39: Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

Jan 2024 - Dec 2024: Data from WAYPOINT trial in chronic rhinosinusitis with nasal polyps
Completed
3
416
Europe, Canada, Japan, US, RoW
Experimental: Tezepelumab, Tezepelumab, Placebo
AstraZeneca, Amgen
Chronic Rhinosinusitis With Nasal Polyps
09/24
12/24
Nair, Arun
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lipworth, Brian
WAYPOINT, NCT04851964 / 2020-003062-39: Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

Jan 2024 - Dec 2024: Data from WAYPOINT trial in chronic rhinosinusitis with nasal polyps
Completed
3
416
Europe, Canada, Japan, US, RoW
Experimental: Tezepelumab, Tezepelumab, Placebo
AstraZeneca, Amgen
Chronic Rhinosinusitis With Nasal Polyps
09/24
12/24
Nair, Arun
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

Terminated
2/3
202
Europe, Canada, US, RoW
AV-101, Placebo
Aerovate Therapeutics, Aerovate Therapeutics, Inc.
Pulmonary Arterial Hypertension
08/24
08/24

Download Options